Source: BioSpace

Sarepta Therapeutics: Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan. 31, 2020

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on January 31, 2020 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2014 Employment Commencement Incentive Plan, as a material inducement to employment to nineteen individuals hired by Sarepta in January 2020.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Based on data from Sarepta Therapeutics's latest SEC filings

Annual Revenue

Based on data from Sarepta Therapeutics's latest SEC filings

Employees

Douglas S. Ingram's photo - President & CEO of Sarepta Therapeutics

President & CEO

Douglas S. Ingram

CEO Approval Rating

89/100

Sarepta develops and commercializes ribonucleic acid targeted therapeutics for the treatment of neuromuscular diseases.

S...
Read more